Article Text

Download PDFPDF
Review
Novel therapies in CIDP
  1. Devan Mair1,2,
  2. Heba Madi1,
  3. Filip Eftimov3,
  4. Michael P Lunn4,5,
  5. Stephen Keddie1
  1. 1Barts Health NHS Trust, London, UK
  2. 2Barts and The London School of Medicine and Dentistry, London, UK
  3. 3Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands
  4. 4MRC Centre for Neuromuscular Disease and Department of Molecular Neuroscience, University College London Hospitals NHS Foundation Trust National Hospital for Neurology and Neurosurgery, London, UK
  5. 5Neuroimmunology and CSF laboratory, Institute of Neurology, University College London Hospitals NHS Foundation Trust, London, UK
  1. Correspondence to Dr Stephen Keddie; stephen.keddie{at}nhs.net

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but clinically well-described disease within circumscribed parameters. It is immunologically mediated through several poorly understood mechanisms. First-line therapies with steroids, intravenous immunoglobulin (IVIG) or plasma exchange are each effective in about two-thirds of patients. These treatments are seldom associated with complete resolution or cure, and often pose considerable practical, financial and medical implications.

Our understanding of many of the key pathological processes in autoimmune diseases is expanding, and novel targeted therapeutics are being developed with promise in several autoimmune neurological disorders.

This narrative review looks first at detailing key pathogenic mechanisms of disease in CIDP, followed by an in-depth description of potential novel therapies and the current evidence of their application in clinical practice.

  • IMMUNOLOGY
  • NEUROIMMUNOLOGY
  • NEUROMUSCULAR
  • NEUROPATHY

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • X @mike_the_nerve

  • Contributors DM and HM were responsible for the literature search and writing of the publication. FE and MPL were responsible for edits and reviews. SK was responsible for the concept, design, edits and reviews.

  • Funding Professor L is supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre

  • Competing interests FE has received funding in grants from CSL Behring, Grifols, Terumo BCT, Takeda, Kendion and the GBS/CIDP foundation. He has also received consultation fees (paid to institution) from Takeda, Dianthus, Sanofi and Argenx. MPL has given advice on ad hoc advisory boards particularly on trial design to Roche, AstraZeneca, Sanofi, UCB, Sanofi, Takeda, Polyneuron and BeiGene (conference expenses and advisory board). Unrestricted conference expenses have been received from Beigene and CSL Behring. He has received research grants from Charitable Foundations: Patrick Berthoud Charitable Trust, ABN, Guarantors of Brain, National Brain Appeal, UCLH Charities, Leonard Wolfson Foundation, Medical Research Council, GBS CIDP Foundation International, New Zealand Medical Foundation, GAIN UK. SK has received conference expenses from CSL Behring.

  • Provenance and peer review Not commissioned; externally peer reviewed.